OPKO's ModeX to present CAR-T cell generation data at gene therapy meeting
ModeX Therapeutics, a subsidiary of OPKO Health, will present preclinical data on its MDX3001 candidate at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston from May 11-15.The data demonstrates in vivo generation of CAR-T cells and B-cell depletion using the company's CD3xCD28 antibody-conjugated lipid nanoparticle/mRNA platform in animal models.
Preclinical Findings and Platform Technology
Studies showed B-cell depletion in blood and lymphoid tissues including spleen, bone marrow, and lymph nodes in both humanized mouse and non-human primate models.The platform combines CD3 with CD28 costimulatory engagement to enable T-cell transfection, activation, and functional CAR-T cell generation directly in vivo.The technology uses antibody-conjugated lipid nanoparticles for cell-specific gene delivery.
"These data demonstrate the strength of our in vivo targeting technology," said John Mascola, Chief Scientific Officer of ModeX Therapeutics."Our antibody-conjugated LNP platform offers a simple and versatile approach to gene delivery for immune cells in vivo, and has the potential to simplify treatment access by eliminating the burden of ex vivo manufacturing."
Gary Nabel, President and CEO of ModeX Therapeutics, stated that the platform "uses proprietary ModeX technology to generate CAR-T cells directly in patients" and "offers a promising clinical modality for diverse diseases, including autoimmunity and oncology."
Presentation Details and Company Background
The oral presentation titled "Bispecific CD3xCD28 Antibody-LNPs Drive In Vivo CAR-T Cell Generation with Deep B Cell Depletion" is scheduled for May 14, 2026 at 10:15 a.m. Eastern time at the Thomas M. Menino Convention Center in Boston.
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing multispecific biologics for cancer, immunology, and infectious diseases.The company is based in Weston, Massachusetts.
